公开(公告)号：US09453253B2

公开(公告)日：2016-09-27

申请号：US14404134

申请日：2013-03-07

Applicant: STC.UNM ,  THE JOHNS HOPKINS UNIVERSITY

Inventor： Graham Timmins ,  Seong Choi ,  Zachary Sharp ,  Viorel Atudorei ,  Mamoudou Maiga ,  William Bishai

IPC: G01N33/60 ,  C12Q1/04 ,  G01N33/569 ,  C12Q1/28

CPC classification number: C12Q1/04 ,  C12Q1/28 ,  C12Q2304/48 ,  G01N33/5695 ,  G01N33/60 ,  G01N2333/35

Abstract: The present invention is directed to methods of diagnosing the presence or absence of a bacterial infection in a patient, in particular, a tuberculosis infection, by measuring exhaled, isotopically labeled nitrogen gas after administration of isotopically labeled isoniazid.

Abstract translation: 本发明涉及通过在施用同位素标记的异烟肼之后测量呼出的，同位素标记的氮气来诊断患者中细菌感染的存在或不存在，特别是结核病感染的方法。

公开(公告)号：US10591491B1

公开(公告)日：2020-03-17

申请号：US16262168

申请日：2019-01-30

Applicant: STC.UNM

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

公开(公告)号：US20200009143A1

公开(公告)日：2020-01-09

申请号：US16310615

申请日：2017-07-24

Applicant: STC.UNM

Inventor： Graham Timmins ,  Ke Jian Jim Liu ,  Xixi Zhou

IPC: A61K31/5025

Abstract: The present invention is directed to the discovery that pyrazinamide, a potent anti-tuberculosis agent acts through an entirely unexpected mechanism-through inhibition of the host enzyme poly ADP ribose polymerase (“PARP”). Thus, the present invention is directed to methods of treating: mycobacterial infections (Mycobacterium), especially M. tuberculosis using a PARP inhibitor, optionally in combination with at least one additional agent useful in the treatment of a mycobacterial infection, especially tuberculosis. Pharmaceutical compositions, especially including a pharmaceutical composition in oral or inhalation dosage form, comprising a inhibitor, optionally in combination with an additional anti-mycobacterial agent, especially an additional anti-tuberculosis agent represent additional embodiments of the present invention.

公开(公告)号：US20190269806A1

公开(公告)日：2019-09-05

申请号：US16412017

申请日：2019-05-14

Applicant: STC.UNM

Inventor： Graham Timmins ,  Vojo P. Deretic

IPC: A61K51/04 ,  A61K35/00 ,  A61P11/00 ,  A61P31/06 ,  A61K31/136

Abstract: The present invention is directed to 13C and/or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an autophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.

公开(公告)号：US10254295B2

公开(公告)日：2019-04-09

申请号：US15463274

申请日：2017-03-20

Applicant: STC.UNM

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

Abstract: Methods and apparatus for determining blood brain barrier (BBB) damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

公开(公告)号：US20150125898A1

公开(公告)日：2015-05-07

申请号：US14596926

申请日：2015-01-14

Applicant: STC.UNM

Inventor： Graham Timmins ,  Terry Wu ,  Seong Won Choi

IPC: C12Q1/04 ,  C07B59/00 ,  C07C275/16

CPC classification number: C12Q1/04 ,  C07B59/001 ,  C07B2200/05 ,  C07B2200/07 ,  C07C275/16 ,  C12Q2304/46 ,  C12Q2304/48

Abstract: The present invention is directed to the use of isotopically labeled citrulline for diagnosing the presence or absence of a bacterial infection in the lungs of a patient.

Abstract translation: 本发明涉及同位素标记的瓜氨酸用于诊断患者肺中细菌感染的存在或不存在的用途。

公开(公告)号：US10583099B2

公开(公告)日：2020-03-10

申请号：US16412017

申请日：2019-05-14

Applicant: STC.UNM

Inventor： Graham Timmins ,  Vojo P. Deretic

IPC: A61K31/137 ,  A61P11/00 ,  A61P31/06 ,  A61K31/136 ,  A61K35/00 ,  A61K51/04 ,  C07C213/08 ,  A61K31/395 ,  A61K9/00 ,  C07C215/42 ,  C07B59/00 ,  A61P31/04 ,  C07C215/68 ,  A61K45/06 ,  A61K45/00

Abstract: The present invention is directed to 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy) are also disclosed. These compositions are useful against an autophagy mediated disease state and/or condition), especially an autophagy mediated disease state and/or condition which occurs in the lungs.

公开(公告)号：US20180169009A1

公开(公告)日：2018-06-21

申请号：US15577572

申请日：2016-06-01

Applicant: Patrick JOHNSON ,  C. Jeffrey BRINKER ,  Eric CARNES ,  Graham TIMMINS ,  Pavan MUTTIL ,  STC.UNM

Inventor： Patrick Johnson ,  C. Jeffrey Brinker ,  Eric Carnes ,  Graham Timmins ,  Pavan Muttil

IPC: A61K9/00 ,  A61K9/16 ,  A61K47/54 ,  C08L23/22 ,  A61K9/12 ,  A61K9/127

CPC classification number: A61K9/0073 ,  A61K9/12 ,  A61K9/1271 ,  A61K9/1617 ,  A61K47/543 ,  C08L23/22

Abstract: This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.

公开(公告)号：US20170199205A1

公开(公告)日：2017-07-13

申请号：US15463274

申请日：2017-03-20

Applicant: STC.UNM

Inventor： Ke Jian Liu ,  Wenlan Liu ,  Graham Timmins ,  Rong Pan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Methods and apparatus for determining blood brain barrier (BBB)damage and treating patients who may have suffered from BBB damage due to an ischemic event are provided. The methods and apparatus involve detecting the presence of cleaved occludin fragments in a sample of blood. According to some embodiments, the method further provides determining the degree of BBB damage based on the concentration of occludin fragments in the sample. In further embodiments the present disclosure provides kits for detecting the presence of occludin fragments in a blood sample.

公开(公告)号：US09579381B2

公开(公告)日：2017-02-28

申请号：US14426543

申请日：2013-09-06

Applicant: STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K31/4409 ,  A61K41/00

CPC classification number: A61K41/0052 ,  A61K31/4409

Abstract: The invention provides method of treating a subject suffering from, or at risk of developing, a Mycobacterium infection by administering to the subject a therapeutically-effective amount of isotopically labeled isoniazid and/or ethionamide, or an analog, derivative or prodrug thereof, and exposing the subject to a magnetic field.

Abstract translation: 本发明提供了通过向受试者施用治疗有效量的同位素标记的异烟肼和/或乙硫异烟胺或其类似物，衍生物或前药，以及暴露于受试者的方法，治疗患有或有发展为分枝杆菌感染风险的受试者 受到磁场的影响。